Virbac SA
Virbac SA manufactures and sells a range of products and services for companion and farm animals in Europe, North America, Latin America, East Asia, India, Africa, the Middle East, and the Pacific. The company offers a range of vaccines, antibiotics, parasiticides, and anti-inflammatory drugs, as well as dermatology, dental, specialty, diagnosis, nutrition, petfood, and pharmaceutical products. I… Read more
Virbac SA (VRBCF) - Net Assets
Latest net assets as of June 2025: $1.07 Billion USD
Based on the latest financial reports, Virbac SA (VRBCF) has net assets worth $1.07 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.82 Billion) and total liabilities ($750.28 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.07 Billion |
| % of Total Assets | 58.67% |
| Annual Growth Rate | 6.27% |
| 5-Year Change | 58.77% |
| 10-Year Change | 116.34% |
| Growth Volatility | 16.38 |
Virbac SA - Net Assets Trend (2002–2024)
This chart illustrates how Virbac SA's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Virbac SA (2002–2024)
The table below shows the annual net assets of Virbac SA from 2002 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $1.04 Billion | +14.67% |
| 2023-12-31 | $909.92 Million | +8.45% |
| 2022-12-31 | $838.98 Million | +15.69% |
| 2021-12-31 | $725.19 Million | +10.35% |
| 2020-12-31 | $657.18 Million | +19.08% |
| 2019-12-31 | $551.88 Million | +11.29% |
| 2018-12-31 | $495.87 Million | +3.56% |
| 2017-12-31 | $478.84 Million | -8.05% |
| 2016-12-31 | $520.79 Million | +7.98% |
| 2015-12-31 | $482.29 Million | +0.11% |
| 2014-12-31 | $481.78 Million | +16.27% |
| 2013-12-31 | $414.37 Million | +4.01% |
| 2012-12-31 | $398.42 Million | +26.94% |
| 2011-12-31 | $313.87 Million | +3.81% |
| 2010-12-31 | $302.35 Million | +28.01% |
| 2009-12-31 | $236.20 Million | +17.50% |
| 2008-12-31 | $201.01 Million | +9.08% |
| 2007-12-31 | $184.28 Million | +11.74% |
| 2006-12-31 | $164.93 Million | +2.96% |
| 2005-12-31 | $160.19 Million | +22.12% |
| 2004-12-31 | $131.17 Million | -56.22% |
| 2003-12-31 | $299.60 Million | +9.43% |
| 2002-12-31 | $273.79 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Virbac SA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 14529000000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | $145.29 Million | 13.93% |
| Common Stock | $10.49 Million | 1.01% |
| Other Components | $887.34 Million | 85.07% |
| Total Equity | $1.04 Billion | 100.00% |
Virbac SA Competitors by Market Cap
The table below lists competitors of Virbac SA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
China Conch Venture Holdings Limited
PINK:CCVTF
|
$1.34 Billion |
|
Peker Gayrimenkul Yatirim Ortakligi AS
IS:PEKGY
|
$1.34 Billion |
|
Taihai Manoir Nuclear Equipment Co Ltd
SHE:002366
|
$1.34 Billion |
|
Killam Apartment Real Estate Investment Trust
TO:KMP-UN
|
$1.34 Billion |
|
Joincare Pharmaceutical Group Industry Co Ltd
SHG:600380
|
$1.34 Billion |
|
Pci-Suntek Technology Co Ltd
SHG:600728
|
$1.34 Billion |
|
North West Company Inc
TO:NWC
|
$1.34 Billion |
|
PCCOF
PINK:PCCOF
|
$1.34 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Virbac SA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 900,301,000 to 1,043,117,000, a change of 142,816,000 (15.9%).
- Net income of 145,290,000 contributed positively to equity growth.
- Dividend payments of 11,054,000 reduced retained earnings.
- Other comprehensive income decreased equity by 760,807,000.
- Other factors increased equity by 769,387,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $145.29 Million | +13.93% |
| Dividends Paid | $11.05 Million | -1.06% |
| Other Comprehensive Income | $-760.81 Million | -72.94% |
| Other Changes | $769.39 Million | +73.76% |
| Total Change | $- | 15.86% |
Book Value vs Market Value Analysis
This analysis compares Virbac SA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.60x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 27.80x to 2.60x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2002-12-31 | $11.65 | $324.00 | x |
| 2003-12-31 | $12.39 | $324.00 | x |
| 2004-12-31 | $14.73 | $324.00 | x |
| 2005-12-31 | $17.46 | $324.00 | x |
| 2006-12-31 | $19.03 | $324.00 | x |
| 2007-12-31 | $21.16 | $324.00 | x |
| 2008-12-31 | $23.04 | $324.00 | x |
| 2009-12-31 | $26.93 | $324.00 | x |
| 2010-12-31 | $34.62 | $324.00 | x |
| 2011-12-31 | $36.99 | $324.00 | x |
| 2012-12-31 | $41.11 | $324.00 | x |
| 2013-12-31 | $42.83 | $324.00 | x |
| 2014-12-31 | $51.12 | $324.00 | x |
| 2015-12-31 | $52.00 | $324.00 | x |
| 2016-12-31 | $56.19 | $324.00 | x |
| 2017-12-31 | $51.82 | $324.00 | x |
| 2018-12-31 | $54.65 | $324.00 | x |
| 2019-12-31 | $61.41 | $324.00 | x |
| 2020-12-31 | $73.84 | $324.00 | x |
| 2021-12-31 | $85.82 | $324.00 | x |
| 2022-12-31 | $99.29 | $324.00 | x |
| 2023-12-31 | $106.71 | $324.00 | x |
| 2024-12-31 | $124.49 | $324.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Virbac SA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 13.93%
- The company shows good efficiency in utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 10.40%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 1.77x
- Recent ROE (13.93%) is below the historical average (15.28%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2002 | 39.17% | 10.81% | 1.38x | 2.63x | $29.63 Million |
| 2003 | 25.50% | 7.76% | 1.24x | 2.64x | $16.74 Million |
| 2004 | 13.66% | 4.76% | 1.19x | 2.40x | $4.48 Million |
| 2005 | 13.37% | 5.32% | 1.18x | 2.12x | $4.99 Million |
| 2006 | 15.31% | 6.20% | 1.06x | 2.33x | $8.64 Million |
| 2007 | 17.03% | 7.08% | 1.16x | 2.07x | $12.82 Million |
| 2008 | 17.84% | 7.99% | 1.07x | 2.08x | $15.57 Million |
| 2009 | 16.62% | 8.30% | 1.08x | 1.86x | $15.46 Million |
| 2010 | 21.13% | 11.07% | 1.07x | 1.78x | $33.41 Million |
| 2011 | 18.47% | 9.23% | 1.06x | 1.89x | $26.38 Million |
| 2012 | 19.25% | 9.58% | 0.84x | 2.39x | $32.01 Million |
| 2013 | 16.77% | 8.22% | 0.82x | 2.48x | $24.43 Million |
| 2014 | 14.76% | 8.23% | 0.58x | 3.08x | $20.50 Million |
| 2015 | 2.15% | 1.10% | 0.60x | 3.26x | $-34.44 Million |
| 2016 | 7.32% | 3.97% | 0.62x | 2.99x | $-12.72 Million |
| 2017 | -0.59% | -0.30% | 0.67x | 2.93x | $-46.21 Million |
| 2018 | 4.37% | 2.31% | 0.68x | 2.77x | $-25.93 Million |
| 2019 | 9.96% | 5.49% | 0.71x | 2.56x | $-228.30K |
| 2020 | 21.84% | 14.56% | 0.84x | 1.78x | $73.75 Million |
| 2021 | 15.61% | 10.64% | 0.89x | 1.66x | $40.67 Million |
| 2022 | 14.53% | 10.03% | 0.91x | 1.59x | $38.03 Million |
| 2023 | 13.47% | 9.73% | 0.86x | 1.62x | $31.27 Million |
| 2024 | 13.93% | 10.40% | 0.76x | 1.77x | $40.98 Million |
Industry Comparison
This section compares Virbac SA's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $308,328,125,500
- Average return on equity (ROE) among peers: 18.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Virbac SA (VRBCF) | $1.07 Billion | 39.17% | 0.70x | $1.34 Billion |
| AbbVie Inc (ABBV) | $13.10 Billion | 35.24% | 10.50x | $390.88 Billion |
| Astellas Pharma Inc (ALPMF) | $1.06 Trillion | 7.80% | 0.36x | $16.93 Billion |
| Amgen Inc (AMGN) | $20.39 Billion | 20.58% | 0.79x | $196.91 Billion |
| Amarin Corporation PLC (AMRN) | $28.90 Million | 14.19% | 0.23x | $303.32 Million |
| AstraZeneca PLC (AZN) | $48.72 Billion | 21.05% | 1.34x | $296.35 Billion |
| Bayer AG (BAYZF) | $31.90 Billion | 14.21% | 1.58x | $21.61 Billion |
| Biogen Inc (BIIB) | $325.20 Million | 9.96% | 0.10x | $26.81 Billion |
| Bristol-Myers Squibb Company (BMY) | $5.08 Billion | 14.69% | 0.67x | $121.36 Billion |
| Chugai Pharmaceutical Co. Ltd (CHGCF) | $1.90 Trillion | 20.37% | 0.16x | $28.30 Billion |
| Cosmo Pharmaceuticals N.V (CMOPF) | $220.16 Million | 31.22% | 0.10x | $529.97 Million |